P&G Health


Zuellig Pharma
Full Prescribing Info
Oxymetazoline hydrochloride.
Rhinological agents (chemically defined), α-sympathomimetic.
Active ingredient (oxymetazoline) has a sympathomimetic, vasoconstrictive, and thus a decongestant effect on the mucous membranes.
The action of Iliadin Drops sets in within a few minutes, with effect persists for up to 12 hours.
Topical vs Oral Nasal Decongestant: (See Table 1.)

Click on icon to see table/diagram/image
Acute cold, paranasal sinusitis, syringitis, otitis media.
Dosage/Direction for Use
(See Table 2.)

Click on icon to see table/diagram/image

Duration of Treatment: Unless specifically prescribed by doctor, Iliadin 0.05%, 0.025% and 0.01% should only be used for short periods of time (5-7 days). A treatment-free period of several days should be preceded by repeated use. Permanent use of decongestant rhinological agents may attenuate their effect. The abuse of local rhinological agents may cause mucosal athrophy and reactive hyperaemia with rhinitis medicamentosa. Longer use of oxymetazoline may cause damage to the mucosal epithelium with inhibition of ciliary activity. This may possible result in irreversible damage to the mucosa with rhinitis sicca. Long term use and overdosage must be avoided, especially in children. Dosage higher than recommended may only be used under medical supervision.
Rhinitis sicca, hypersensitivity to the active ingredient or to any of the excipients.
Risk-to-benefit ratio must be weighed for use in the following cases: Patients treated with MAO-inhibitors and other drugs potentially increasing blood pressure, increased intraocular pressure (esp. narrow-angle glaucoma), severe CV disease (e.g. coronary heart disease, hypertension), phaeochromocytoma, metabolic disorders (e.g. hyperthyroidism, diabetes mellitus, porphyria, hyperplasia of the prostate).
Contains benzalkonium chloride as preservative, must not be used in known hypersensitivity to this substance.
Special Precautions
Medical supervision is indicated in patients with chronic rhinitis. Should only be used after consultation with a physician during pregnancy and lactation. The recommended dosage must not be exceeded. No impairment on ability to drive and use machineries is to be expected if used as recommended. Systemic effects with CV involvement cannot be excluded after prolonged administration or intake of oxymetazoline-containing cold remedies in doses higher than recommended. In these cases, the ability to drive a vehicle or operate machinery can be impaired.
Use In Pregnancy & Lactation
During pregnancy and lactation the recommended dosage should not be exceeded and the preparation should be only used after carefully weighing the risk-to-benefit ratio.
Side Effects
Occasionally, burning or dryness of the nasal mucosa, sneezing. In rare cases - after the effect has worn off – an intense sensation of "blocked" nose (reactive hyperaemia). With topical intranasal use, overdosage leads occasionally to systemic sympathomimetic effects like palpitations, accelerated pulse (tachycardia) and increase in blood pressure. Restlessness, insomnia, tiredness and headaches have been observed in very rare cases. Epistaxis, apnoea in newborns and in young infants (esp. in case of overdosage), hallucinations and convulsions.
Drug Interactions
The concomitant use of oxymetazoline containing nasal drops and medicines with hypertensive effect (e.g. MAO-inhibitors and tricyclic antidepressants) may lead to an increase in blood pressure due to their cardiovascular activity. Overdosage or swallowing of Iliadin and use of tricyclic antidepressants or MAO-inhibitors simultaneously or immediately prior to administration of Iliadin drops can lead to an increased blood pressure.
MIMS Class
Nasal Decongestants & Other Nasal Preparations
ATC Classification
R01AA05 - oxymetazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
Nasal drops (baby drops) 0.01% x 5 mL; (children drops) 0.025% x 10 mL; (adult drops) 0.05% x 10 mL.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in